anti-tumor vaccines
Anti-cancer vaccines
anti-tumor immune responses
tumor peptides
personalized anti-cancer vaccine
cancer patients
anti-PDL1
cancer treatment
cancer immunotherapy
cancer cells
personalization of PeptiCrad
Personalized oncolytic vaccines
restricted tumor-specific peptides
specific immune response
immune checkpoint inhibitors anti-CTLA4
generic virus infection strategies
Oncolytic viruses
specificity of vaccines
significant questions
significant impact
personalized approaches
novel vaccine platform
development
addition
grant
primary tumors
strengths of OVs
cytokines
promising approach
cytolysis
great potential
preliminary results
translational capability
MHC
immunomodulatory molecules
feature
application
distant metastases
lines of research
chemical manipulation
current state
capsid
shortcoming
efficacy
project
adenovirus
reason
end
technology
immunity
method